(Q45107740)

English

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection

scientific article published on 31 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection (English)

1 reference

Europe PubMed Central

9 December 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Seol Hee Hong

1

1 reference

Europe PubMed Central

9 December 2017

Young-Ho Byun

2

1 reference

Europe PubMed Central

9 December 2017

Chung Truong Nguyen

3

1 reference

Europe PubMed Central

9 December 2017

Soo Young Kim

4

1 reference

Europe PubMed Central

9 December 2017

Baik Lin Seong

5

1 reference

Europe PubMed Central

9 December 2017

Songyong Park

6

1 reference

Europe PubMed Central

9 December 2017

Gyu-Jin Woo

7

1 reference

Europe PubMed Central

9 December 2017

Yeup Yoon

8

1 reference

Europe PubMed Central

9 December 2017

Jeong Tae Koh

9

1 reference

Europe PubMed Central

9 December 2017

Kohtaro Fujihashi

10

1 reference

Europe PubMed Central

9 December 2017

Joon Haeng Rhee

11

1 reference

Europe PubMed Central

9 December 2017

Shee Eun Lee

12

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

31 October 2011

1 reference

Europe PubMed Central

9 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

9 December 2017

30

1 reference

Europe PubMed Central

9 December 2017

2

1 reference

Europe PubMed Central

9 December 2017

466-474

1 reference

Europe PubMed Central

9 December 2017

Influenza vaccines for the future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

A review of vaccine research and development: human acute respiratory infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Estimating influenza-associated deaths in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Vaccination strategies to promote mucosal antibody responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Influenza vaccination among the elderly in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Defending the mucosa: adjuvant and carrier formulations for mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Pathogen recognition and innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Recognition of microorganisms and activation of the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

TLR-based immune adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Role of secretory antibodies in the defence against infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Cross‐Reactive H1N1 Antibody Responses to a Live Attenuated Influenza Vaccine in Children: Implication for Selection of Vaccine Strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Inhibition of airway allergic disease by co-administration of flagellin with allergen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Sublingual vaccination with influenza virus protects mice against lethal viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.058

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.10.058

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45107740&oldid=2066210513"